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Abstract
The clinical complications of malaria are caused by the parasite expansion in the blood.
Invasion of erythrocytes is a complex process that depends on multiple receptor-ligand
interactions. Identification of host receptors is paramount for fighting the disease as it could
reveal new intervention targets, but the enucleated nature of erythrocytes makes genetic
approaches impossible and many receptors remain unknown. Host-parasite interactions
evolve rapidly and are therefore likely to be species-specific. As a results, understanding of
invasion receptors outside the major human pathogen Plasmodium falciparum is very lim-
ited. Here we use mouse embryonic stem cells (mESCs) that can be genetically engineered
and differentiated into erythrocytes to identify receptors for the rodent malaria parasite Plas-
modium berghei. Two proteins previously implicated in human malaria infection: glyco-
phorin C (GYPC) and Band-3 (Slc4a1) were deleted in mESCs to generate stable cell lines,
which were differentiated towards erythropoiesis. In vitro infection assays revealed that
while deletion of Band-3 has no effect, absence of GYPC results in a dramatic decrease in
invasion, demonstrating the crucial role of this protein for P. berghei infection. This stem cell
approach offers the possibility of targeting genes that may be essential and therefore diffi-
cult to disrupt in whole organisms and has the potential to be applied to a variety of parasites
in diverse host cell types.
Introduction
Malaria is a devastating infectious disease caused by Plasmodium parasite species that cycle
between humans and Anophelesmosquitoes. While the parasite’s life cycle is complex, it is the
infection of erythrocytes which is responsible for the symptoms and complications of the dis-
ease [1, 2]. Plasmodium species are obligate intracellular parasites that exist only briefly as an
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extracellular form, the merozoite, during the blood stages. The process by which merozoites
recognise and enter erythrocytes is highly complex and depends on a sequence of steps deter-
mined by specific molecular interactions. Initially, attachment to the erythrocyte membrane
occurs through ligands distributed across the merozoite surface. A reorientation then places
the apical end of the parasite into close contact with the erythrocyte membrane, where a dense
junction forms followed by an active entry process [3, 4].
The complexity of the invasion process clearly relies on multiple receptor-ligand interac-
tions between erythrocyte and merozoite, but relatively few such interactions have been identi-
fied and characterised at the molecular level. Furthermore, these interactions are likely to be
highly species-specific, so what is known about interactions in one Plasmodium species cannot
be directly transferred to another. Most is known about the parasite that causes the majority of
human malaria mortality, P. falciparum, which uses a number of receptor-ligand interactions
to facilitate invasion, some of which appear to be redundant. Its genome encodes multiple
members of the erythrocyte binding-like (EBL) and reticulocyte binding-like (RBL) invasion
ligand families, which have been identified in every Plasmodium species sequenced to date [5].
Receptors have been identified for some of these proteins, such as PfEBA175 which interacts
with the predominant erythrocyte surface sialoglycoprotein Glycophorin A [6], PfEBA140
which interacts with Glycophorin C (GYPC), a component of the Gerbich blood group
involved in maintaining the shape and membrane properties of erythrocytes [7, 8] and PfRH5
which interacts with basigin, the determinant of the Oka blood group [9]. By contrast, there is
no evidence that many other species including the other most abundant human parasite, P.
vivax, use these proteins for invasion. Instead, this species critically depends on P. vivax Duffy
Binding Protein (PvDBP), which binds to the Duffy Antigen Receptor for Chemokines
(DARC) [10, 11]. Though DARC was also shown to be an important mediator of infection by
the simian parasite P. knowlesi[12, 13] as well as the more distantly related rodent parasite P.
yoelii [14], in these species, it is not essential. Therefore, the use of receptors across species can-
not be predicted based on phylogenetic distance alone. Other erythrocyte proteins are thought
to play a role in invasion, although their function is not always clearly defined. The anion trans-
porter Band-3 (Slc4a1) is a type IV membrane-spanning surface protein that is thought to
interact with P. falciparumMSP1 and MSP9 proteins and therefore may be directly involved in
invasion [15, 16] although other roles are also possible. This protein harbours a 9 amino acid
deletion in Southeast Asian Ovalocytosis, a condition associated with resistance to cerebral
malaria [17–19] although the exact mechanism involved in resistance is not yet clear [20].
Whether Band-3 is important in other Plasmodium species is not known, and hard to predict
due to the species-specificity of these interactions and for many commonly studied Plasmo-
dium parasites, including the widely used rodent model P. berghei, no receptors have been thus
far indetified.
For many commonly studied Plasmodium parasites, including the widely used rodent
model P. berghei, no receptors have been thus far indentified. Part of the challenge of identify-
ing receptors is technical. Some biochemical approaches have been attempted, relying on pro-
tein binding or co-immunoprecipitation, but the often low affinity of surface protein-protein
interactions makes their identification difficult [21]. Other studies used erythrocytes from
human genetic variants with specific surface proteins phenotypes, but these are limited by the
relatively rare occurrence and scarce availability of such cells [22–24]. Stem cells provide a
promising alternative since genetic changes can be introduced during the pluripotent state and
the modified cells can then be differentiated into erythrocytes to assess the impact of these
changes on Plasmodium infection. Pioneering studies testing this approach have been per-
formed using human haematopoietic stem cells (HSCs) in which shRNA knockdown of spe-
cific erythrocyte proteins was shown to restrict invasion by P. falciparum, recapitulating
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known receptor preferences as well as identifying novel host determinants of the disease [25,
26]. Here we explore the potential of mouse Embryonic Stem Cells (mESCs) as a genetic system
to identify host factors involved in the rodent model of malaria using Plasmodium berghei
infection.
mESCs are diploid pluripotent cells derived from the inner cell mass of the blastocyst at the
early stages of embryogenesis. They can be cultured and expanded in vitromaintaining their
self-renewal and pluripotency indefinitely. Since mESCs are stably kept in the laboratory, per-
manent genetic manipulation is possible and because they are pluripotent, they have the ability
to give rise to all three germ layers of an organism: endoderm, mesoderm and ectoderm [27]
and differentiate into various cell types including functional erythrocytes [28, 29]. Here, we
combine genetic manipulation of mESCs, erythropoietic differentiation and Plasmodium infec-
tion assays to investigate host-parasite interactions in the model rodent parasite P. berghei. We
focus on two erythrocyte proteins, Glycophorin C (GYPC) and Band-3 (Slc4a1), aiming to
include an abundant membrane protein and structural component of the erythrocyte. These
proteins are localised in different complexes on the erythrocyte membrane and though no
direct parallels can be drawn, there is evidence for their participation in the invasion process in
several Plasmodium species. Our results show that while Band-3 does not appear to play a role,
GYPC is crucial for P. berghei invasion.
Materials and Methods
Embryonic Stem Cell culture
The JM8.N4 cell line, derived from the mouse strain C57BL/6N [30], was cultured on 0.1% gel-
atin coated plates (Corning NY, USA) in Knockout DMEM (Gibco, UK) containing 2mM
L-Glutamine (Gibco, UK), 0.05mM β-mercaptoethanol (Sigma Dorset, UK), 10% fetal bovine
serum (Biosera East Sussex, UK) and 1000U/ml LIF (ESGRO, Millipore Watford, UK), at 370
and 5% CO2, changing medium daily. Cells are detached with 0.1% trypsin (Gibco, UK), con-
taining 1% chicken serum (Gibco, UK), 0.6 mM EDTA (Sigma Dorset, UK) and 0.1% D-glu-
cose (Sigma Dorset, UK) and passaged every two to three days. The E14 mESC line (129P2
background) was cultured in the same way but using GMEM with the addition of pyruvate and
keeping the cells in 7% CO2.
Embryoid Body formation
Cells were re-suspended (2x106cells/ml) and cultured in Hyclone IMDM (Thermo Scientific,
UK) with 15% Fetal Bovine Serum, 10% PfHMII (Gibco, UK), 2mM L-Glutamine solution
(Gibco, UK), 300μg/ml Holo-Transferrin (Sigma Dorset, UK), 50μg/ml Ascorbic Acid (Sigma
Dorset, UK), 0.4mMMTG (Sigma Dorset, UK) and 1ng/ml mouse IL-3 (Gibco, UK) [28], in
100mmx20mm bacterial plates (Sterilin Newport, UK). EBs were cultured for 6 days, adding
fresh medium half way through.
Erythroid Differentiation
EBs were dissociated by trypsinisation and the resulting single cell suspension taken through a
3 step differentiation protocol [29] as follows:
Expansion medium I. StemPro134 SFM (Gibco, UK) with 1μMDexamethasone (Life
Sciences, UK), 1.5U/ml EPO (Sigma Dorset, UK), 100ng/ml mouse SCF (BioLegend London,
UK), 40ng/ml mouse IGF1 (Shenandoah Biotechnology Inc Warwick, UK) and 10ng/ml
mouse IL-3 (Gibco, UK). Cells were cultured at a density of 106cells/ml for 4 to 5 days.
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Expansion medium II. StemPro134 SFM (Gibco) with 1μMDexamethasone (Life Sci-
ences, UK), 1.5U/ml EPO (Sigma Dorset, UK), 100ng/ml mouse SCF (BioLegend London, UK)
and 40ng/ml mouse IGF1 (Shenandoah Biotechnology Inc Warwick, UK). Cells were cultured
for 4 days or until they stopped proliferating, centrifuged at 200 xg for 3 minutes at room tem-
perature and washed x3 with sterile PBS before changing into the differentiation medium.
Differentiation medium. StemPro134 SFM (Gibco, UK), 10U/ml erythropoietin (Sigma
Dorset, UK), 40ng/ml mouse IGF1 (Shenandoah Biotechnology Inc Warwick, UK), 0.5µg/ml
human Holo-Transferrin (Sigma Dorset, UK) and 10μg/ml human Insulin. Cells were counted
on a regular basis using a hemocytometer and diluted 1:10 in Hyclone Trypan Blue Solution
(Thermo Scientific, UK).
RNA extraction and RT-PCR analysis
Total RNA was extracted using the Bioline (London, UK) isolate RNA kit following the manu-
facturer’s instructions and quantified on a NanoPhotometer1. RNA (1–3μg) was reverse tran-
scribed with a MuLV reverse transcriptase (Applied Biosystems, UK) and random primers
(Bioline, UK). One μl of cDNA was specifically and quantitatively amplified using the Sybr-
Green system (Applied Biosystems UK) following the established cycling parameters and using













Flow Cytometry (FACS) analysis
Pluripotency analysis was performed with the BD Stemflow™Human and Mouse Pluripotent
Stem Cell Analysis Kit (BD Biosciences Oxford, UK). Specific surface markers were assessed
with fluorochrome-labelled specific antibodies after blocking Fc non-specific interactions by
incubation with an anti-CD16/32 antibody for 10–15 minutes. Parameters for analysis were set
with unlabelled cells and gating with isotype controls for the appropriate fluorochromes. Com-
pensation for spectral overlap was done when required using BD™ CompBead Plus positive
and negative beads. Analysis was run on a LSFORTESSA BD cytometer using Flowjo (7.6.5).
Antibodies: CD71-FITC; CD117-APC; CD41-FITC; CD33-PE (BD pharmingen); CD61-PE
(Caltag); CD45-Pacblue (biolegend); CD34-FITC (Cambridge Bioscience); CD14-APC
(ebioscience)
Haemoglobin staining
Cells smeared on glass slides were fixed with methanol and incubated in the stain solution
(40% ethanol, 0.01M sodium acetate, 0.65% hydrogen peroxide and 0.6 mg/ml o-dianisidine
SIGMA) for 15 minutes at room temperature. The slides were washed with water and imaged
on a light microscope (Leica).
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P. berghei schizont culture and purification
All animal procedures were conducted under UK Home Office project licence and approved
by the ethics committee of Wellcome Trust Sanger Institute. The experimental protocols
performed during this work were classified as "mild" according to the severity categories
guidance (Home Office,UK). All animals were monitored daily and showed no symptoms
of the malaria infection or any other health issues. The biological material was harvested
on the final day under terminal anaesthesia and animals were euthanised immediately
afterwards.
The P. berghei ANKA (line 1804cl1) parasites that express mCherry under the Hsp70 pro-
moter, received from Dr. Chris Janse (Leiden malaria research group, the Netherlands) was
used for these studies. C57BL/6N mice were pre-treated with 25mg/ml phenylhydrazine to
enrich for reticulocytes and, two days later, injected with 107 mCherry-P. berghei parasites.
Blood was collected and used for schizont culture as described previously [31]. Parasites puri-
fied on a Nycodenz gradient were re-suspended in differentiation medium, assessed by micros-
copy and mechanically ruptured to release the merozoites.
Invasion Assay
Prior to the invasion assay, ‘target’ cells can be stained with carboxy-DFFDA,SE dye (CellTra-
ceTM Invitrogen, UK). Cells were centrifuged at 1250xg for 3 minutes, washed once and incu-
bated in differentiation medium containing 5μMDFFDA-SE for 2 hours at 37°C. The cells
were washed twice and incubated for a further 30 minutes at 37°C. After a short spin as above
the cells were resuspended in fresh medium, ready for the invasion assay.
Differentiated cells were centrifuged at 1250 xg for 5 minutes. 5x105 cells were resuspended
in 50μl of medium and dispensed in one well of a rounded bottom 96 well sterile plate (Corning
NY, USA). To this culture 5x105 ruptured schizonts were added to a final volume of 100μl. The
plate was gassed with malaria gas (1% O2, 3% CO2, 96% N2; BOC Guildford UK) in a closed
chamber and incubated at 37°C over 24 hours. Mouse uninfected blood was used as a control
for each experiment.
Genomic manipulation of mouse ESCs
Conditional heterozygous knockout mESC lines were obtained from the European Conditional
Mouse Mutagenesis Program (EUCOMM) resource [32]. Targeting was confirmed with spe-
cific PCR primers and by the Taqman1 Copy number assay or loss of allele (LOA) assay [33].
Additionally, euploidy of the most frequently aberrant chromosomes 1, 8, 11 and Y was
confirmed.
The second alleles were targeted with final vectors assembled from intermediate constructs
from the EUCOMM resource: a custom L1L2 containing β-actin promoter-blasticidin followed
by a 3’ loxP site (gift from Peri Tate, WITSI) and L3L4 backbone. Gateway reactions were
assembled and transformed into Cre expressing E. coli as described previously [33]. Cre-
recombinase was induced with a heat-shock the next morning at 42°C for 30 minutes and the
bacteria were plated on YEG-Cl agar with 0.4% glucose and 50μg/ml spectinomycin. Colonies
were picked and the final vector from which the loxP-flanked critical region is deleted was
extracted and confirmed by restriction digests. The final vectors were prepared and electropo-
rated into mESCs following the above protocol. Colonies were selected with 100μg/ml G418 as
well as 1μg/ml blasticidin (Fisher BioReagents, UK) for selection of homozygous cells. Selected
colonies were expanded and genotyped.
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Western Blot
Western blots were run as described previously [34] and Glycophorin C expression was
assessed with and anti-GYPC antibody (PAB711Mu01, Cloud-Clone Corp, USA) and an HRP-
conjugated goat anti rabbit secondary antibody (SIGMA).
Confocal microscopy
After invasion, the samples were fixed in 4% paraformaldehyde (Fisher Scientific, Loughbor-
ough UK) for 20 minutes, washed with PBS and permeabilised with 0.1% TX100 in PBS for 10
min. Blocking was done with 3% BSA in PBS for 30 min followed by an anti-MSP1 antibody,
generously donated by Dr. A. Holder [35] for 2 hours. After washing x3 in PBS-3% BSA the
cells were incubated with a secondary Alexa Fluor 488-conjugated goat anti-mouse IgG (Invi-
trogen, USA) for 1 hour and washed x3 again. The cells were smeared on glass slides, mounted
using prolong gold DAPI medium (Invitrogen USA) and left to set over night. Slides were ana-
lysed on a confocal microscope (Zeiss LSM 510 meta).
Statistical analysis
Values are presented as means and standard deviation. Any reported significance was calcu-
lated using a two-tailed unpaired Student’s t-test analysis.
Results
mESCs differentiate into erythroid cells in vitro
The mouse embryonic stem cell (mESCs) line JM8.N4, derived from the mouse strain C57BL/
6N was differentiated into erythroid cells in vitro using a protocol based on previously
described work [28, 29]. Feeder-free JM8 ESCs normally grow in colonies (Fig 1A top panel)
expressing the pluripotency markers Oct3/4 and SSEA-1 while very low levels of the general
differentiation marker SSEA-4 are detected. Specific haematopoietic markers such as CD34,
CD45 and CD71 are also very low at this stage as measured by flow cytometry (Fig 1A middle
panel).
The first step of the differentiation protocol is the formation of embryoid bodies (EBs) con-
sisting of tight three-dimensional aggregates of cells (Fig 1B top panel). At this stage, expres-
sion of pluripotency markers decreases and concomitantly some of the crucial mesodermal
and haematopoietic regulatory transcription factors such as GATA-1 and Tal-1 become more
prominent, as measured by qRT-PCR (Fig 1B bottom panel).
Subsequently, the EBs are disaggregated into a single cell suspension which is taken through
a three step differentiation protocol to generate erythroblasts and finally erythroid cells (Fig 1C
top panel). Flow cytometry analysis of the cell population for haematopoietic markers shows
no significant differentiation towards the myeloid (CD14, CD33) nor megakaryocytic (CD41,
CD61) cell types and a small persistence of haematopoietic progenitor cells of approximately
10% witnessed by CD117 labelling (not shown). On the other hand, erythroid markers CD71
and TER119 show increased expression (Fig 1C middle panel). Of particular importance is
CD71 that reveals erythroid cells in earlier stages of differentiation which are known to be pref-
erentially infected by P. berghei [36]. Efficient definitive erythroid differentiation is demon-
strated by a high increase in the transcription levels of adult globin genes (haemoglobin-α and
β) as shown by qRT-PCR (Fig 1C bottom panel). Morphologically, rapid Romanowski stain
reveals a heterogeneous population in the in vitro differentiated cells (Fig 2A) in which haemo-
globinisation is confirmed by 0-dianisidine staining (Fig 2B). Flow cytometry analysis shows
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prevalence of nucleated cells (Fig 2C) indicating that the differentiated cells are mainly at a
stage of erythroid progenitors.
In vitro differentiated mESCs support P. berghei infection
In order to assess infection of differentiated cells in vitro, we developed an invasion assay
adapting previously described protocols [37, 38]. Briefly, P. berghei schizonts of the ANKA
1804cl1 line that express mCherry under the Hsp70 promoter, are purified, mechanically dis-
rupted and mixed with differentiated cells or blood. The cultures are then incubated for 24
hours under gas and temperature conditions suitable for parasite development. This time
period covers the whole intraerythrocytic cycle of P. berghei during which samples are taken at
6 and 24 hours to measure initial invasion and subsequent development.
At the first time point of 6 hours, Romanowski staining shows ring stage parasites in the dif-
ferentiated cells, morphologically similar to those observed in mouse blood (Fig 3A). The 24
hour time point reveals the development of schizonts that are also similar between the differen-
tiated cells and mouse blood. The presence of parasites inside differentiated mESCs was con-
firmed by MSP-1 staining with specific antibodies and compared to parasites in in vitro
Fig 1. Differentiation of JM8mESCs towards erythropoiesis. A) top panel: pluripotent JM8 cell growth
under light microscopy;middle panel: analysis of the indicated cell surface markers by flow cytometry. B)
top panel: morphology of embryoid bodies under light microscopy; bottom panel: analysis of
haematopoietic markers by qRT-PCR. C) top panel: differentiated erythroid cells under light microscopy,
black arrow indicates haemoglobinised colony of cells;middle panel: analysis of cell surface markers by flow
cytometry; bottom panel: haematopoietic proteins by qRT-PCR. (Data are presented as mean +/-SD).
doi:10.1371/journal.pone.0158238.g001
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infected primary mouse erythrocytes (Fig 3B). A proteolytic fragment of this merozoite surface
protein (MSP1-19) is carried into the infected erythrocyte and recognised by the monoclonal
antibody [35]. At 6 hours post-infection, the expected small ring pattern of MSP1 staining
around the parasite is visible, while at 24 hours parasites with the characteristic morphology of
schizonts, can be detected.
The use of mCherry-expressing parasites allows invasion events to be quantified using flow
cytometry (Fig 3C). Debris and doublets were excluded from the analysis using FSC-A/SSC-A
followed by FSC-A/FSC-W and SSC-A/ SSC-W to establish gating of the populations (an
example of the gating strategy is shown in S1 Fig, all samples were analysed in the same way).
The infection levels detected in the differentiated cells are similar to those observed in mouse
blood. In both types of host cells infection levels decrease at the late time point of 24 hours pre-
sumably due to the degeneration of some of the formed schizonts together with the known
inability of P. berghei to re-invade in vitro.
Genome editing of mouse ESCs can target genes implicated in malaria
infection
To test whether this stem cell system could be used to identify genes involved in P. berghei
invasion, two genes were targeted in mESCs which encode two major components of the eryth-
rocyte membrane: the Band-3 anion transporter (Slc4a1) and Glycophorin C (GYPC).
JM8.N4 cell lines in which one allele of GYPC had been targeted were obtained from the
European Conditional Mouse Mutagenesis Program (EUCOMM) resource [32]. The ‘knock-
out first allele’ in the EUCOMM resource has a gene trap reporter/selection cassette introduced
in an intron immediately before a critical exon (exon 2), that forces premature transcription
Fig 2. Analysis of differentiated JM8 erythroid cells. A) Rapid Romanowski stain of mouse blood and
differentiated cells. B) Staining Haemoglobin in mouse blood and differentiated cells with o-dianisidine. C)
Flow cytometry detection of nuclei in blood and differentiated cells labelled with Hoechst 33342.
doi:10.1371/journal.pone.0158238.g002
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termination of the targeted gene resulting in a null allele (S2A Fig). The EUCOMM cell line
was re-cloned and targeting of the first allele was confirmed by the Taqman1 Copy number
assay (loss of allele assay, LOA) and PCR (S2A Fig). Making use of the modular design of the
intermediate targeting vectors from the EUCOMM resource, we generated a construct for
Fig 3. Invasion of in vitro differentiated erythroid cells by P. berghei. A) Rapid Romanowski staining of
infected red blood cells and mESC-derived erythroid cells 6 h and 24 h post-infection. B) Confocal
microscopy of mouse erythrocytes and in vitro generated erythroid cells infected with P. berghei. Parasites
are labelled with an anti-MSP1 antibody followed by a AF488-conjugated secondary antibody and nuclei are
stained with DAPI. Invasion is followed at 6 and 24 hours. C) Flow cytometry quantification of infected cells by
detecting mCherry-expressing parasites. The plots show the populations distribution for an example
experiment and the bar charts are the result of at least three separate experiments. Data are presented at
mean +/-SD.
doi:10.1371/journal.pone.0158238.g003
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homologous recombination into the second allele of GYPC from which the critical exon 2 has
been deleted (S2B Fig). The blasticidin resistance gene (BlastR) was introduced as an additional
selection marker to allow recovery of double targeted clones, which were verified by LOA (S2B
Fig) [39]. Ablation of transcription as well as protein synthesis was confirmed by qRT-PCR
andWestern Blot (S3 Fig).
This strategy was unsuccessful for the targeting of Slc4a1 in the JM8 ESC line due to geno-
mic instability resulting in a high trisomy frequency of chromosome 11 in which Slc4a1 is
located. We obtained from Skarnes and collaborators E14 mESC lines (129P2 background) in
which Slc4a1 has been deleted. These lines were constructed using CRISPR/Cas9 technology to
induce damage in both alleles of the gene caused by NHEJ. Correct targeting of the resulting
clones was verified by Sanger sequencing that showed a 1bp insertion in clone D06 and a 1bp
deletion in clone F06, causing a frameshift (S4 Fig). This intervention obliterated transcript
and protein synthesis as confirmed by qRT-PCR and flow cytometry (S5 Fig).
Genetically modified ESCs can be differentiated into erythrocytes
Pluripotency of the modified mESC lines was confirmed by FACS and qRT-PCR (not shown).
The lines were differentiated following the protocol described above in parallel with the corre-
sponding wild type mESCs as controls. Inactivation of the target genes in each line was con-
firmed in the differentiated cells by qRT-PCR (S2 Fig). As expected, no transcript was detected
in pluripotent cells, while once differentiated into erythrocytes, high expression was observed
in the wild type lines. Only background mRNA levels were detectable in cells differentiated
from the GYPC-/- and Slc4a1-/- lines, confirming the successful deletion of the target genes,
and by inference absence of the translated protein.
Differentiation of the KO lines generates a heterogeneous population of cells similar to that
observed with differentiated wild type cells. Expression of haematopoietic markers as assessed
by FACS shows increased CD34 as well as high levels of CD71 on the membrane of both differ-
entiated KO lines (Fig 4A). A high induction of the adult haemoglobins α, β and γ, similar to
the levels observed in the wild type cell lines is detected confirming successful differentiation
towards erythropoiesis (Fig 4B).
Fig 4. Eyrthropoietic differentiation of genetically modified cell lines. A) Flow cytometric quantification of
haematopoietic markers in the differentiated GM lines. B) qRT-PCR quantification of haematopoietic protein
transcripts in differentiated GM lines. Data are presented as mean +/-SD. See also S1 Fig.
doi:10.1371/journal.pone.0158238.g004
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Gene disruption generates different phenotypes of infection
Differentiated wild type E14 and JM8 ESCs as well as the Slc4a1-/- and GYPC-/- lines derived
from them, were infected with P. berghei in vitro. Confocal immunofluorescence microscopy
confirmed MSP1 labelling characteristic of rings at 6 hours post-infection and the presence of
some schizonts at the end of the 24 h cycle in the KO cell lines for both genes (Fig 5A), though
the frequency and size of the parasites is smaller in the GYPC-/- cell line (Fig 5A right panel).
Two independently generated clones for each inactivated gene were tested for their ability
to support P. berghei infection. Quantification by flow cytometry shows that inactivation of
Slc4a1 does not affect the capacity of P. berghei to infect these cells (Fig 5B left panel). In order
to verify that the edited differentiated cells are indeed invaded by the parasite, they were
labelled with the cell tracker DFFDA-SE before the invasion assay (S6 Fig). Counting of
Fig 5. Infection of differentiated genetically modified cell lines with P. berghei. A) Infection of Slc4a1-/-
and GYPC-/- differentiated cells. Labelling with MSP-1 and confocal microscopy showing parasites in the
cells. B) Flow cytometric quantification of m-cherry-parasite positive cells at 6 and 24 hours. The plots show
the populations distribution for an example experiment and the bar charts are the result of at least three
separate experiments (* P<0.01 and ** P>0.1 comparing the clones at each time point with WT). Data are
presented as mean +/-SD. See also S6 Fig.
doi:10.1371/journal.pone.0158238.g005
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double-labelled events, representing DFFDA-cells infected with mCherry-parasites, confirms
that P. berghei is capable of invading in vitro differentiated Band-3 KO mESCs. Though sur-
vival of the parasites in the Slc4a1-/- cells seems higher at 24 hours, this effect is not significant
(P>0.1). In marked contrast, the ability of GYPC KO cells to support P. berghei infection is
dramatically reduced by 66% at 6 hours and by 86% at 24 hours (P<0.01) (Fig 5B right panel),
indicating that this is an important receptor for the rodent parasite, just as it is for P. falcipa-
rum [7, 8].
Discussion
In this work we use a stem cell-based strategy to investigate host factors of a rodent malaria
model. With this technology we are able to generate genetically edited erythroid cells that sup-
port infection with P. berghei in vitro. These are largely immature nucleated cells that may dif-
fer in some aspects from erythrocytes, just as most in vitro Plasmodium culture systems do not
reflect the true diversity and heterogeneity of the host cells encountered by parasites in vivo.
However, just as the latter, the stem cell-based strategy describe here offers great potential for
the understanding of the host proteins implicated in malaria infection. We show that inactiva-
tion of Band-3 in mouse erythrocytes does not affect invasion by P. berghei, in strong contrast
to infection by P. falciparum which is inhibited by deficiency of this protein (reviewed in [40]).
This emphasises the specificity of host-parasite interactions and the difficulties of inferring
function from one Plasmodium species to another at such a rapidly evolving interface. The abil-
ity to examine the function of Band-3 in a knock out cell line highlights the potential of this
strategy, which allows manipulation of essential genes that are lethal in whole organisms or
inaccessible in terminally differentiated cell types devoid nuclei. Homozygous mutations affect-
ing the function of Band-3 are not known to occur naturally and though a KO mouse for
Band-3 has been generated, 85 to 90% of the mice die neonatally. The surviving animals suffer
extreme anaemia, low body weight and splenomegaly [41, 42], which makes their use for
malaria infection studies very difficult. In humans, mutations leading to a decrease of Band-3
expression are found exclusively in heterozygosis [43], and some (as the Southeast Asian Ova-
locytosis) have been linked with resistance to malaria infection [17–19]. Only one case of a
homozygous mutation (Coimbra) leading to a complete absence of Band-3 has been described
in a human patient [44], with reported serious health conditions and dependency on systematic
transfusion. Furthermore, Band-3 forms a membrane complex with other proteins such as gly-
cophorin A (GYPA), Rh and CD47 on the erythrocyte plasma membrane. In studies of eryth-
rocytes from the Coimbra mutation patient it was noticed that the loss of Band-3 is
accompanied by a loss of membrane expression of the other members of this complex includ-
ing GYPA [44, 45]. The same dependency of Glycophorin A on Band-3 membrane localisation
was observed in mouse erythrocytes [46] and implies that P. berghei does not depend on GYPA
to invade mouse erythrocytes, contrary to P. falciparum which is well known to use GYPA as
one of its main invasion receptors [6]. This is consistent with previous data showing that the
murine Plasmodium parasites P. berghei and P. chabaudi do not require GYPA to invade
mouse reticulocytes [47].
In human erythrocytes GYPC is part of a protein complex distinct from the Band-3-GYPA
complex, so GYPC membrane localisation is not affected by deficiency of Band-3 [45]. Our
data shows that knock out of GYPC dramatically decreases invasion, indicating that, in con-
trast to Band-3 and GYPA, this protein is crucial for P. berghei infection. GYPC is also impli-
cated in invasion by P. falciparum, but it appears to play a less important role. P. falciparum
uses several pathways to invade human erythrocytes [48, 49] and blockage of the GYPC path-
way is most effective when others are inhibited at the same time (reviewed in [50]). The
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dramatic decrease in P. berghei infection of GYPC-/- differentiated cells suggests a much
heavier dependency on GYPC for invasion in this species and that alternative invasion path-
ways may be either missing or less important. P. falciparum recognises human GYPC through
PfEBA140, a member of the EBL ligand super-family. The P. berghei genome contains one EBL
family protein with homology to PfEBA140 (PBANKA_1332700) which is a clear candidate
for interaction with GYPC. However, there are several members of the RBL ligand super-family
in the P. berghei genome that could alternatively be binding partners.
Conclusion
Taken together, our results highlight species-specific differences in invasion pathways and
identify a major receptor for P. berghei. Our work shows that stem cells are a useful model for
the analysis of the host components of infectious diseases and strengthens the field together
with other studies that have used haematopoietic stem cells to knock down erythrocyte surface
proteins to identify host factors required for P. falciparum invasion [26]. The system presented
here has the advantage of generating stable cell lines with permanent genetic changes in a stable
background that can be repeatedly used as a continuous source for study. On the other hand,
as the erythroid cells are differentiated in vitro, they are nucleated and physiologically distinct
from primary erythrocytes, which could influence their interation with the parasite and have
an impact on the infection outcome. The development of new mutagenesis technologies that
increase the efficiency and specificity of targeting, especially the CRISPR/Cas9 system, further
increases the value of this strategy. Targeting of difficult and essential genes becomes possible
achieving a clean and complete inactivation resulting in a true null phenotype difficult to
obtain with other technologies. Of particular interest for future development are inducible sys-
tems that allow ‘turning off’ the desired genes at specific times, for example once the cells are
differentiated. We demonstrate that various ESC lines from different backgrounds can be dif-
ferentiated towards erythropoiesis, which also opens the possibility of exploiting existing
resources of knock out mice as a supply of stem cell lines to be analysed in this way. Further-
more, since stem cells are pluripotent, provided good differentiation protocols can be designed,
this strategy could be exploited to explore other stages of the pathogen’s life cycle that are nor-
mally inaccessible in vitro, such as the liver stages in the case of Plasmodium parasites [51].
Finally, as human pluripotent cells also have the capacity to differentiate to the haematopoietic
lineage [52], extending our approach to a direct functional interrogation of human parasites
such as P. falciparum is a clear and exciting possibility.
Supporting Information
S1 Fig. Flow cytometry gating strategy. A) Debris was eliminated using SSC-A/FSC-A scatter
plots. Doublets were excluded using B) FSC-W/FSC-A and C) SSC-A/SSC-W plots.
(TIF)
S2 Fig. Genotyping of the Glycophorin C deletion clones. A) Diagram of the vector used to
target the first allele. The colonies recovered were tested for vector integration by PCR, using
the indicated primers. The copy number of the gene of interest was determined by Loss Of
Allele assay (LOA). B) Diagram of the vectors used to target the second allele and LOA to con-
firm GYPC-/- clones.
(TIF)
S3 Fig. Confirmation of inactivation of Glycophorin C. A) Glycophorin C transcript accu-
mulation by qRT-PCR, in wild type (WT) cells upon differentiation (Diff) compared to the
GYPC-/- clone. B) Western blot of differentiated JM8 cells WT and two knock out clones for
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GYPC 37 and 89.
(TIF)
S4 Fig. Genotyping of the Slc4a1 edited clones. Sequence shows defects in red and traces con-
firm the damage caused.
(TIF)
S5 Fig. Confirmation of inactivation of Slc4a1 (Band-3). A) Band 3 transcript accumulation
in wild type (E14) and Slc4a1-/- (SLC) cell lines at the pluripotent (E14, SLC), embryoid body
(EB) and differentiated (Diff) stages using 2 sets of primers, one located upstream the critical
region (SLC3) and one downstream (SLC5). B) Western blot od differentiated E14 cells WT
and two knock out clones D06 and F06.
(TIF)
S6 Fig. Invasion assay with labelled Slc4a1 differentiated cells and mCherry-expressing P.
berghei. Differentiated E14 cells, wild type and two knock out clones for Band-3 were labelled
with the cell tracker DFFDA-SE prior to infection with mCherry-expressing P. berghei para-
sites. The time points of 6 and 24 hours were followed and analysed by flow cytometry.
(TIF)
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